Skip to main content
Midas Edge

MyMD Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

QCLS$0.37+8.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Shareholders’ Equity

Consolidated Statement of Changes in Stockholders’ Equity

For the Years Ended December 31, 2023 and 2022

Series F Convertible · Series D Convertible
Preferred Stock · Preferred Stock · Common Stock
Shares · Series F · Shares · Series D · Shares · Common Stock $0.001 Par Per Share · Additional Paid In Capital · Accumulated Deficit · Total Equity
Balance at December 31, 2022-$-72,992$144,5241,315,674$1,316$108,308,120$(93,758,904)$14,695,056
Net loss-------(3,999,950)(3,999,950)
Round-up shares from the 1-for-30 reverse split effective February 23, 2024----65,96066(66)--
Issuance of common stock for vested restricted stock units----7,8618(8)--
Exercise of prepaid equity forward contract----4,5054(4)--
Issuance of 15,000 shares of Series F Convertible Preferred Stock, net of discount and offering costs of $14,087,11115,000912,889-------
Conversion of 1,250 shares of Series F Convertible Preferred Stock, July 1, 2023 installment of $1,429,871 paid with common stock(1,250)(76,074))--39,58740255,906-255,945
Conversion of 1,250 shares of Series F Convertible Preferred Stock, August 1, 2023 installment of $1,429,871 paid with common stock(1,250)(76,073))--38,68839255,905-255,944
Conversion of 1,250 shares of Series F Convertible Preferred Stock, September 1, 2023 installment of $1,429,871 paid with common stock(1,250)(76,074))--67,73268255,877-255,945
Conversion of 1,187 shares of Series F Convertible Preferred Stock, October 1, 2023 installment of $1,429,871 paid with common stock(1,187)(63,659))--58,45058214,118-214,175
Accelerated Conversion of 204 shares of Series F Convertible Preferred Stock(204)(12,416))--10,5501041,759-41,770
Accelerated Conversion of 416 shares of Series F Convertible Preferred Stock(416)(26,249))--41,6724288,271-88,313
Redemption of 772 shares of Series F Convertible Preferred Stock for cash(772)(49,824))------
Accelerated Conversion of 570 shares of Series F Convertible Preferred Stock(570)(36,263))--100,007100121,905-122,005
Redemption of 617 shares of Series F Convertible Preferred Stock for cash(617)(39,811))-------
Accelerated Conversion of 851 shares of Series F Convertible Preferred Stock(851)(52,375))--182,848183176,030-176,213
Deemed Dividend for the true-up of the August 1, 2023 installment for the Series F Convertible Preferred Stock paid with common stock----29,04529766,474(766,503)-
Deemed Dividend for the true-up of the October 1, 2023 installment for the Series F Convertible Preferred Stock paid with common stock----56,2785666,273(666,329)-
Series F Convertible Preferred Stock Dividend-------(2,785,381)(2,785,381)
Stock based compensation - stock options------3,049,537-3,049,537
Balance at December 31, 20236,633$404,07172,992$144,5242,018,857$2,019$114,200,096$(101,977,067)$12,369,572
Series F Convertible · Series D Convertible
Preferred Stock · Preferred Stock · Common Stock
Shares · Series F · Shares · Series D · Shares · Common Stock $0.001 Par Per Share · Additional Paid In Capital · Accumulated Deficit · Total Equity
Balance at December 31, 2021-$-72,992$144,5241,255,777$1,256102,062,962$(78,561,568)$23,647,174
Net loss-------(15,197,336)(15,197,336)
Net proceeds from private placement of 47,059 common shares, net of offering costs $ 449,500----47,059475,549,981-5,550,028
Exercise of prepaid equity forward contracts for Common Stock----12,83813(13)--
Stock-based compensation – restricted stock units------165,997-165,997
Stock-based compensation – stock options------444,342-444,342
Stock-based compensation – warrants------84,851-84,851
Balance at December 31, 2022--72,992$144,5241,315,674$1,316108,308,120(93,758,904)14,695,056

The accompanying notes are an integral part of these consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.